Additionally, the SOLTI-1303 PATRICIA study of palbociclib and trastuzumab in HR+/HER2 + advanced breast cancer showed that the Luminal A and B subtypes benefited substantially from palbociclib, while the HER2-enriched group had very small absolute benefit19. This evidence concerns the gene ERBB2 and breast cancer.